Navigation Links
First Pediatric Patient Treated With Aptocine(TM), a Novel Light-Activated Drug, in Neurofibromatosis Study
Date:8/12/2009

BELLEVUE, Wash., Aug. 12 /PRNewswire/ -- Light Sciences Oncology, Inc. (LSO) today announced the treatment of the first patient in an investigator-sponsored Phase 1 pediatric study of its novel light-activated drug Aptocine(TM) (talaporfin sodium) in neurofibromatosis type 1 (NF-1). Investigators at the Neurofibromatosis/Neuro-Oncology Clinic of Children's Hospital of Philadelphia (CHOP) treated a pediatric patient with NF-1 and plexiform neurofibromas (PN) using Aptocine, which is also in late-stage development for solid tumors. The Neurofibromatosis/Neuro-Oncology Clinic is a program providing care and treatment for children with brain tumors and children with NF-1 and severe and/or life-threatening tumors. Michael Fisher, M.D., at CHOP's Division of Oncology, is the principal investigator of the study.

"A clinical trial in neurofibromatosis is an exciting step forward in the development of Aptocine for patients with a significant unmet medical need outside our primary cancer focus. I am proud and delighted that LSO is now associated with developing a treatment of this condition in children and adults," said LSO's President and CEO, Llew Keltner, M.D., Ph.D.

The goal of the study is to enroll 18-24 patients between 3 and 21 years of age with debilitating, severely disfiguring, life-threatening, or progressive PN tumors that are not surgically resectable, and for which no other standard medical management exists. Complete information on the study is available at ClinicalTrials.gov with the identifier: NCT00716469.

NF-1 is a common, autosomal dominant genetic disorder with an incidence of 1 in 2500 people (> 80,000 in the US); symptoms of NF-1 usually appear at birth and/or during infancy. PN represents one of the most significant complications of NF-1. PN tumors form along peripheral nerves and can become very large. Although PN tumors are not a major cause of mortality in pati
'/>"/>

SOURCE Light Sciences Oncology, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related biology technology :

1. Jennerex Closes $5 Million First Tranche of Series C Financing
2. William Stanfield, MD, Is First Cleveland-area Orthopedic Surgeon to Perform OtisKnee Custom Fit Knee Replacement
3. Imagenetix, Inc. Reports First Quarter 2010 Results
4. Synthetech Reports First Quarter Fiscal 2010 Results
5. Repligen Reports First Quarter Fiscal Year 2010 Financial Results
6. Nile Therapeutics, Inc. Announces Dosing of First Patient in Phase 2 Study of CD-NP for the Treatment of Acute Heart Failure
7. Hoya Announces First Quarter Financial Results for FY2010
8. Trubion Announces Dates for Second Quarter and First Half 2009 Earnings Conference Call
9. Repligen Announces Conference Call of First Quarter Fiscal Year 2010 Results
10. First genetically engineered malaria vaccine to enter human trials
11. First U.K. Stem Cell Awareness Rally to Take Place in Manchester, England on August 9th, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2012)... to voice concern on biosimilars pathways for patients with ... offered oral testimony at last week,s U.S. ... guidance of biosimilars products. IDF urged the FDA to ... order to protect the safety of patients with PIDD. ... an immune system that is either absent or hindered ...
(Date:5/16/2012)... May 16, 2012  UV Flu Technologies, ... to announce that it has signed a television ... San Bernardino Ca., for the filming of a ... "mini-infomercial." The commercial will run locally, regionally, and ... Comcast and Direct TV. The commercials will be ...
(Date:5/16/2012)... MAHWAH, N.J., May 16, 2012 /PRNewswire-Asia-FirstCall/ -- Mindray ... a leading developer, manufacturer and marketer of medical ... L.P., (HealthTrust) is renewing its agreement for its ... With this agreement, Mindray provides monitoring that ... hospital departments and outpatient surgery centers for HealthTrust ...
(Date:5/15/2012)... Vermillion, Inc. (NASDAQ: VRML ), ... results for the first quarter ended March 31, 2012. ... In Q1, the volume of OVA1®, the company,s flagship ... ovarian masses, was generally in line with the forecast ... increase of 28% to 3,952 from the same year-ago ...
Breaking Biology Technology:Immune Deficiency Foundation Urges FDA To Exempt Immunoglobulin From Biosimilars Pathway 2UV Flu Technologies to Commence a National TV Advertising Campaign 2UV Flu Technologies to Commence a National TV Advertising Campaign 3Mindray Renews Agreement with HealthTrust Purchasing Group, L.P. to Provide Patient Monitoring Equipment 2Vermillion Reports First Quarter 2012 Results 2Vermillion Reports First Quarter 2012 Results 3Vermillion Reports First Quarter 2012 Results 4Vermillion Reports First Quarter 2012 Results 5Vermillion Reports First Quarter 2012 Results 6Vermillion Reports First Quarter 2012 Results 7Vermillion Reports First Quarter 2012 Results 8
... COLUMBUS, Ohio -- Engineers at Ohio State University are ... from the same material found in pencils. , Experts ... found in graphite pencils -- holds the key to ... effects that could enable new kinds of electronics. , ...
... VIEW, Calif., March 31 Based on its recent analysis ... Polymers LLC with the 2009 North American Frost & Sullivan ... to lead innovation in the field of styrenic block copolymers ... over four decades, the company,s new family of SBCs, the ...
... Pharmaceuticals, Inc. (NYSE: WPI ), a leading ... District Court for the District of Delaware has ruled ... tablets) does not infringe United States Patent No. 6,919,373 ... invalid. The opinion, dated March 30, 2009, was ...
Other Biology Technology:Researchers find better way to manufacture fast computer chips 2Researchers find better way to manufacture fast computer chips 3Frost & Sullivan Recognizes Kraton Polymers for Developing a New Generation of Polymer Grades Suitable for High-Speed Processing in Nonwoven Manufacture 2Frost & Sullivan Recognizes Kraton Polymers for Developing a New Generation of Polymer Grades Suitable for High-Speed Processing in Nonwoven Manufacture 3Frost & Sullivan Recognizes Kraton Polymers for Developing a New Generation of Polymer Grades Suitable for High-Speed Processing in Nonwoven Manufacture 4Frost & Sullivan Recognizes Kraton Polymers for Developing a New Generation of Polymer Grades Suitable for High-Speed Processing in Nonwoven Manufacture 5Delaware Court Rules That Watson Does Not Infringe Patent Related to Generic Version of Concerta(R) and Declares Patent Invalid 2
(Date:5/21/2012)... 2012  Chiltern International Limited (Chiltern), a global ... been recognized with a CRO Leadership Award in ... Regulatory. The awards are given by Life Science ... Nice Insight. Glenn Kerkhof ... be recognized as a CRO leader in the ...
(Date:5/21/2012)... (WHOI) have conducted a new study to measure levels ... The study, recently published in the journal Biogeosciences ... the Arctic Ocean,s carbon cyclethe pathway through which carbon ... will also offer an important point of reference for ... and how the ecosystem responds to rising global temperatures. ...
(Date:5/21/2012)... FLA.Robert van Woesik, Florida Institute of Technology professor ... grant from the National Science Foundation for research ... project will develop quantitative approaches to assess the ... are decimating the corals. When diseases cluster they ... a secondary cause of infection., Although diseases are ...
Breaking Biology News(10 mins):Chiltern Wins CRO Leadership Award From Life Science Leader 2New study by WHOI scientists provides baseline measurements of carbon in Arctic Ocean 2New study by WHOI scientists provides baseline measurements of carbon in Arctic Ocean 3Acne Psoriasis Meds Dont Raise Fracture Risk 72216 1Survey Finds Those Over 50 Are Less Stressed 72213 1Survey Finds Those Over 50 Are Less Stressed 72213 2Survey Finds Those Over 50 Are Less Stressed 72213 3Euthanasia and the use of end of life drugs without explicit request 72210 1Euthanasia and the use of end of life drugs without explicit request 72210 2
... and Switzerland has shown that carbon nanotubes may be ... 21 in the advance online edition of the journal ... in the search to find ways to "bypass" faulty ... which, like neurons, are highly electrically conductive, form extremely ...
... BOSTON, Mass. (Dec. 21, 2008) Modern humans left Africa ... was responsible for nearly all of the human population that ... that men and women weren,t equal partners in that exodus. ... non-sex chromosomes, the researchers found evidence that men probably outnumbered ...
... Washington, DC U.S. Forest Service Southern Research Station ... Presidential Early Career Award for Scientists and Engineers during ... among the nearly 70 scientists and engineers receiving the ... scientist or engineer can receive in the United States. ...
Other Biology News:New 'smart' materials for the brain 2Haag honored with Presidential Early Career Scientists Award 2
Anti-Chicken IgY, (IgG) F(ab')2 Fragment Specific....
Presenilin 2 Immunogen: Synthetic peptide corresponding to residues 31-47 of human Presenilin 2. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Recognizes TWIK-2. Does not cross react with any other known proteins....
Sheep polyclonal to ErbB 2 ( Abpromise for all tested applications). Antigen: Recombinant full length c-ErbB2 protein (Human). Entrez GeneID: 2064 Swiss Protein ID: P04626...
Biology Products: